Evidence map›Paper›PMID 35792949›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds.

Alex C Spyropoulos, Bríain Ó Hartaigh, Zhun Cao, Harjeet Caberwal, Craig Lipkin, Michaela Petrini, Cheng Wang

Open access · goldAbstract read
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2023
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Alex C SpyropoulosInstitute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.ORCID https://orcid.org/0000-0002-3175-461X
Bríain Ó Hartaigh6893Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Zhun Cao43690Premier, Inc, Charlotte, NC, USA.
Harjeet Caberwal6893Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Craig Lipkin43690Premier, Inc, Charlotte, NC, USA.
Michaela Petrini6893Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Cheng Wang6893Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Boehringer Ingelheim (United States) · USPremier Research Group · USNorthwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anticoagulation ReversalHemorrhageAdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnticoagulantsFactor XaFactor Xa InhibitorsHumansIntracranial HemorrhagesPatient Acceptance of Health CareRecombinant ProteinsRetrospective StudiesAntibodies, Monoclonal, HumanizedAnticoagulantsFactor XaFactor Xa InhibitorsidarucizumabPRT064445Recombinant Proteinsandexanet alfaanticoagulationcosthealthcare resource utilizationidarucizumabreversal

Identifiers

PMID35792949
PMCPMC9272054
OpenAlexW4284707619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.